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Abstract: New DNA sequencing platforms have revolutionized human genome sequencing. 
The dramatic advances in genome sequencing technologies predict that the $1,000 genome 
will become a reality within the next few years. Applied to cancer, the availability of 
cancer genome sequences permits real-time decision-making with the potential to affect 
diagnosis, prognosis, and treatment, and has opened the door towards personalized 
medicine. A promising strategy is the identification of mutated tumor antigens, and the 
design of personalized cancer vaccines. Supporting this notion are preliminary analyses of 
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the epitope landscape in breast cancer suggesting that individual tumors express significant 
numbers of novel antigens to the immune system that can be specifically targeted through 
cancer vaccines. 
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1. Introduction 
In 2001, two research groups reported the completion of the first draft assemblies of the human 
genome sequence [1,2]. Ten years after this milestone achievement, massively parallel DNA 
sequencing (so-called “next-generation”) technologies have transformed genome sequencing, 
significantly, decreasing both the cost and time required to sequence human genomes, and by 
extension cancer genomes. However, the overall impact of cancer genome sequencing on human 
health has not been fully realized. In this review, we discuss the evolution of cancer genome 
sequencing and its potential application towards the development of personalized cancer vaccines. 
2. Evolution of DNA Sequencing Technologies 
DNA sequencing technology has made great advances over the past 30 years since the development 
of the chain-terminating “Sanger method” [3,4]. The first draft of the human genome [1,2] was 
produced largely by Sanger-based capillary electrophoresis technology. Sequencing the entire genomes 
of organisms using the Sanger method has proven to be difficult and time consuming. Through 
significant refinements and automation, the current Sanger method-based instruments are able to 
deliver read lengths up to 1,000 bases and allow 384 samples to be sequenced in parallel within a few 
hours. Therefore, even using the most advanced Sanger sequencers, it would take years and millions of 
dollars to sequence a human genome. 
However, the field has changed rapidly since the commercial introduction of several “massively 
parallel” or next-generation platforms, starting in 2004. The technical details of the next-generation 
DNA sequencing technologies are beyond the scope of this review but have been described  
elsewhere [3-6]. In general, next-generation sequencing platforms produce shorter sequencing reads 
with slightly lower per base accuracy than data from Sanger-based DNA sequencing, and as such 
require increased coverage depths. These shorter read depths also complicate read-based assembly as a 
means of genome sequencing for more complex genomes (such as human). As such, all human 
genome sequencing with next-generation methods relies on alignment of the sequencing reads to the 
human reference sequence as a precursor to identifying mutations or other genomic alterations. Thanks 
to the ever-growing computing power and advances in instrument design, recent years have seen major 
increases in speed (Table 1) and reduction in cost (Figure 1) for next-generation methods, although the 
cost of analysis of next-generation sequencing data has not decreased as dramatically. 
The future of DNA sequencing looks even more promising as new technologies continue to emerge 
(Table 1). For example, Complete Genomics has developed a “DNA nanoball” sequencing technology 
that uses fluorescent probe ligation chemistry similar to the SOLiD platforms. However, instead of an 




emulsion PCR step, the method uses rolling circle replication to amplify small DNA fragments into 
“DNA nanoballs” [7,8]. In a pH-based sensing system similar to the Roche/454 pyrosequencing 
technology, Ion Torrent’s Personal Genome Machine is a simple, scalable and fast machine that 
“reads” DNA without requiring optical detection [9]. The Helicos’ system generates sequence 
information by capturing images of fluorescent step-wise DNA synthesis reactions from individual 
molecules, without prior DNA amplification [10]. This approach avoids sequencing errors attributable 
to PCR artifacts, but has an inherently higher error rate than amplified DNA technologies, due to 
noise-related artifacts that are unique to single-molecule sequencing. In 2010, Pacific Biosciences 
introduced its “third generation” sequencing product, the PacBio RS which also is a single molecule 
sequencing platform. The RS uses nanofabricated structures called “zero mode waveguides” or ZMWs 
to focus the instrument optics on individual DNA polymerases as they copy single molecules of DNA 
by incorporating fluorescent nucleotides. These real-time movies of DNA polymerization can result in 
read lengths in excess of 1,500 base pairs, although the error rate also is higher as a result of  
single-molecule detection sources of noise [11]. Both the Ion Torrent and Pacific Biosciences 
instruments have lower yields of sequencing data per run than other massively parallel sequencing 
instruments at this time, and are not suited for whole human genome sequencing. These new 
technologies may further reduce time and/or the cost of genome sequencing. 
Table 1. Summary of DNA sequencing platforms 1. 
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1 Typical performances of selected model systems are listed based on the marketing materials from 
each company. Actual results may vary depending on specific sample and genomic characteristics; 
2 Not commercially available. Complete Genomics offers in-house sequencing services bundled 
with web-based data analysis; 3 Output per chip; 4 Based on Enterobacteria phage λ at 45 Mb/SMRT 
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tumor antigens. We propose an innovative new paradigm: development of personalized cancer 
vaccines targeting unique tumor antigens identified by genome sequencing. Next-generation DNA 
sequencing technologies have fundamentally transformed cancer genome sequencing, as outlined 
above. These innovative technologies also provide an unprecedented opportunity to rapidly identify 
unique tumor antigens toward the goal of a personalized cancer vaccine for each patient. 
4.1. What is a Unique Tumor Antigen? 
Tumor antigens are often classified as “unique” or “shared” tumor antigens, according to their 
distribution in normal or in neoplastic tissues (Table 2). Shared tumor antigens are expressed in 
multiple cancers, and are often self-differentiation antigens that are expressed in a limited subset of 
normal tissues, but overexpressed in cancers. Examples of shared tumor antigens include MAGE 
(melanoma) [29], prostatic acid phosphatase (prostate cancer) [30], and HER2/neu (breast cancer) [31]. 
They also include mutated oncogenes or tumor suppressor genes, or chromosomal translocations 
encoding novel fusion proteins such as K-Ras, p53, and BCR-ABL, respectively. 
Table 2. Unique and shared tumor antigens. 
Characteristics Unique TA Shared TA 
Expression in tumor single tumor multiple tumors 
Mutation yes no * 
Expression in normal tissue no yes 
Risk for autoimmunity no yes 
Predicted T cell affinity high moderate to low 
Applicability to tumor targeting universal restricted 
Resistance to immunoselection yes no 
* Exceptions are mutations in oncogenes/tumor suppressor genes such as K-RAS and p53. 
Unique tumor antigens are only expressed in a single cancer, and are typically the result of point 
mutations or other genetic changes present only in the tumor [32,33]. As such, unique tumor antigens 
represent the only true tumor-specific antigens that are not expressed in any normal tissues. In mice, 
unique tumor antigens were described many years ago in models of chemical or UV-induced 
fibrosarcomas. These tumors were rejected through T cell-mediated immunity upon transplantation in 
syngeneic hosts. The immune response was found to be unique to each tumor which led to the concept 
that such tumors express unique tumor-specific transplantation antigens [32,33]. In 1995, the first 
unique tumor antigens in humans were identified in melanoma [34,35]. Since that time additional 
publications have described the expression of unique tumor antigens in melanoma [36], non-small cell 
lung cancer [37] and other human cancers [33,38]. Not surprisingly, unique antigens are typically 
encoded by genes that regulate cellular processes such as cell cycle, metabolic pathways, and others 
that are hallmarks of tumor development and survival [17]. 
To date, no unique tumor antigens have been identified in breast cancer. Current experimental 
techniques are biased towards the identification of shared tumor antigens such as HER2/neu [39,40], 
MUC1 [41], and mammaglobin-A [42-44], and no experimental techniques are capable of rapidly or 
systematically identifying unique tumor antigens. Next-generation DNA sequencing technologies 




provide an unprecedented opportunity to identify unique tumor antigens. Key questions to be 
addressed in this evolving paradigm are: (1) Are unique tumor antigens identified by genome 
sequencing processed and presented by the immune system? (2) Can CD8+ T cells recognize these 
unique tumor antigens? (3) Is there evidence of a pre-existing immune response to unique tumor 
antigens in breast cancer patients? 
4.2. Targeting Unique Tumor Antigens: Conceptual Advantages 
Once shared tumor antigens were discovered, there was a race to translate the use of these antigens 
into the clinic, and the majority of cancer vaccine trials performed to date have targeted shared tumor 
antigens. Unfortunately, the results of these studies have been disappointing [45,46], despite the ability 
of some vaccines to generate a high frequency of self/tumor antigen-specific T cells [47]. It is now 
known that the T cell repertoire is edited during development to minimize autoimmunity, and that  
T cells specific to shared tumor antigens can display low affinity for antigen. This may partially 
explain the low success rate of cancer vaccines to date, as low affinity T cells are weak effectors, and 
also are known to promote the expansion of regulatory T cells [48]. Thus, identification of unique 
tumor antigens not edited by the immune system may elicit more effective T cell responses with 
increased effector functions. 
Cancer vaccine strategies targeting unique tumor antigens have substantial advantages over 
strategies targeting shared tumor antigens [32,33] (Table 2). (1) Targeting unique tumor antigens is 
safer. Unique tumor antigens are expressed only in the tumor, decreasing the risk of autoimmunity;  
(2) Targeting unique tumor antigens is more effective, because T cell responses to unique tumor 
antigens are high in affinity, and are not limited by mechanisms of self-tolerance; (3) Targeting unique 
tumor antigens may limit antigen-loss, a common tumor escape mechanism. One of the hallmarks of 
cancer is genome instability, which may cause the loss of antigen expression on the tumor and thereby 
recognition by immune cells. As such, one clear weakness of cancer vaccines that target a single 
shared tumor antigen is antigen-loss. An unbiased strategy, in which all unique tumor antigens are 
targeted by a vaccine may circumvent antigen-loss and preclude immune escape. In addition, many 
unique tumor antigens play a functional role in neoplastic transformation (so-called driver mutations). 
Immune selection resulting in loss of driver mutations may fundamentally alter the phenotype of 
targeted cancers; (4) Finally, targeting unique tumor antigens is universally applicable. For example, 
all histologic types of cancer appear to have remarkable numbers of candidate unique tumor antigens, 
suggesting that a personalized vaccine approach could be applied to treat all types of cancer, regardless 
of intrinsic subtype. 
4.3. Targeting Unique Tumor Antigens: Experimental Data 
Experiments with mouse antigens have revealed two mechanisms whereby genetic mutations can 
generate antigenic peptides [29-31,34]. In one scenario, the mutation transforms a non-MHC binding 
peptide into one that has a high binding affinity for a particular MHC class I allele. Alternatively, the 
mutation can alter peptide residues that interact with the T cell receptor (TCR) on T cells. These 
mutated peptides can activate T cells with a TCR repertoire distinct from those that recognize the 
self/non-mutated peptide. 




Results from various clinical studies have indicated patients undergoing immune therapy can 
develop responses to unique tumor antigens. For example, T cells specific for unique antigens have been 
identified in clinically responding melanoma patients treated with adoptively transferred T cells [33]. 
Similarly, patients with metastatic renal cell carcinoma developed specific T cells to mutated peptides 
encoded by the von Hippel-Lindau (VHL) gene after peptide vaccination [49]. Somatic mutations in 
VHL have been observed in over 60% of patients with sporadic renal cell carcinoma. 
The most compelling evidence to date of the immunogenicity of unique tumor antigens comes from 
human clinical trials in patients with follicular lymphoma. In this disease, the hypervariable region of 
the clonotypic antibody represents a unique tumor antigen. Because of its consistent location, this 
unique tumor antigen can be readily identified with standard molecular biology techniques, and a 
personalized idiotype vaccine showed considerable promise in phase I/II clinical trials [50]. A 
randomized phase III clinical trial of a personalized idiotype vaccine has recently been completed. 
Patients with advanced stage follicular lymphoma that had been previously untreated were treated with 
standard chemotherapy. Patients with a complete response were randomly assigned to receive an 
idiotype vaccine conjugated to KLH, or a control vaccine without idiotype. Preliminary results 
demonstrated a significant prolongation in the median time to relapse (44.2 vs. 30.6 months; P = 0.045, 
hazard ratio = 1.6) [51], illustrating the potential of immune responses to unique tumor antigens. 
4.4. The Epitope Landscape of Unique Tumor Antigens 
Investigators have tried to develop high throughput strategies for the identification of unique tumor 
antigens [52]. Unfortunately, these strategies (differential gene expression analysis of tumor and 
corresponding normal tissue, in combination with acid elution of HLA molecules and mass 
spectrometry) are too impractical for routine use and require significant amounts of tumor tissue. Until 
the advent of cancer genome sequencing, there were no practical experimental techniques for the rapid 
and/or systematic identification of unique tumor antigens, and as such, an experimental bias may be 
responsible for the underrepresentation of unique tumor antigens in the scientific literature [53]. 
As the generation of mutations in tumor cells is continuous due to imperfect DNA replication and 
repair, one would predict the presence of multiple unique tumor antigens in tumor cells during tumor 
progression. Supporting this prediction is a recent in silico-based prediction analysis of the epitope 
landscape in breast and colorectal cancer [54]. A set of somatic mutations termed the consensus coding 
sequences that represent highly curated genes identified in breast and colorectal cancers [55] were 
analyzed for the presence of T cell epitopes to HLA-A2 using epitope prediction algorithms such as 
BIMAS [56]. Based on this analysis, it was predicted that individual breast and colorectal cancers 
accumulate an average of 10 and seven unique HLA-A*0201 epitopes, respectively. As individual 
cells potentially express six distinct HLA class I alleles, the total number of new epitopes was 
estimated to range from ~60 to ~42 in each breast and colorectal cancer, respectively. It should be 
noted that these are theoretical numbers; for example, it was not assessed in this study whether these 
epitopes are actually expressed by tumors, and whether the mutated proteins are processed and 
presented to immune cells. 
Since then, several tumor genome sequencing studies have been completed that permit the search 
for unique tumor antigens in actual tumors. The first such study focused on the sequencing and 




comparative analysis of a tumor and normal genome from patients with AML for the unbiased 
discovery of tumor-specific somatic mutations that alter the protein-coding genes [14,57,58]. More 
recently, massively parallel DNA sequencing was used to sequence and compare four DNA samples 
(primary tumor, brain metastasis, xenograft of the primary tumor, and peripheral blood) from a patient 
with basal-like breast cancer [13]. Massively parallel sequencing technologies are particularly well 
suited to cancer genome sequencing. Breast cancer is a heterogenous disease, but genome sequencing 
at an almost 40× haploid coverage provides the opportunity to precisely calculate mutant allele 
frequencies, demonstrating genome remodeling, and unexpected similarities between the brain 
metastasis and xenograft [13]. We performed “epitope landscape” analyses based on the genomic 
analyses of primary tumor and peripheral blood DNA samples from a patient with basal-like breast 
cancer (Table 3). Following validation, we identified 37 candidate unique tumor antigens associated 
with an alteration in the amino acid sequence (nonsynonymous mutations). Amino acid sequences 
reflecting the mutation plus 10 flanking residues on each side were screened for binding to HLA-A2 
(the breast cancer patient sequenced in these studies is HLA-A2+) using two prediction algorithms [52,56]. 
These algorithms have proven to be reliable predictors of HLA class I binding, particularly for 
frequently expressed alleles such as HLA-A2. Three candidate unique tumor antigens are predicted to 
be strong binders (predicted affinity <50 nM), while 12 are predicted to be weak binders (predicted 
affinity 50–500 nM). Thus, 40% of the candidate unique tumor antigens have the potential to bind 
HLA-A2. Of note, the HLA type of the patient under investigation is A*02, 33; B*15(71), 35; C*03, 07. 
We performed similar analyses to predict if candidate unique tumor antigens are capable of binding to 
HLA alleles other than HLA-A2. Taken together, 17 strong binders and 45 weak binders were 
identified for the six HLA class I alleles (data not shown). Overall, 32/37 of the candidate unique 
tumor antigens (86%) were predicted to bind at least one HLA allele. 
Table 3. Unique tumor antigens identified through breast cancer genome sequencing and 







Amino Acid Sequence 2 
Predicted Affinity 3 
mutated wild type 
DDX11 12; 31122692 SNV (T > G) QEDFMAELYRGLEAGKIGIFE 15 25 
PTCH2 1; 45068225 SNV (C > G) CHGFSHKFMHSQEELLLGGMA 26 21 
PARVA 11; 12496610 insertion SFAFELMQDGMEGLEKPKPRPE 32 18192 
JAK2 9; 5040714 SNV (T > C) QWRHDFVHGWTKVPVTHETQE 55 31 
DYNC2H1 11; 102687902 SNV (G > A) EQISKKDNTHQAHALFSLAWF 60 19004 
CMV pp65 N/A N/A NLVPMVATV 4 N/A 60 
PPPDE1 1; 242935580 SNV (A > T) LQSCLPKEWLSPAALQSSVSQ 65 102 
SHE 1; 152723308 deletion AVFDSIPEVVHYYSLSKGQNT● 5,6 66 18757 
SLC44A1 9; 107137789 SNV (G > A) LKTLSDVQKFTEINGSALCSY 94 82 
JAK2 9; 5040714 SNV (T > C) QWRHDFVHGWTKVPVTHETQE 111 291 
NALCN 13; 100688137  SNV (A > T) VIGTTLHVYPELYHSQFTYFQ 127 1293 
GP100280 N/A N/A YLEPGPVTA 4 N/A 135 
GUK1 1; 226395989 SNV (C > A) MAGSQKEEIMQPQQGVPFQES 162 331 
DHDDS 1; 26646672 SNV (G > A) FLNVCFAYTSHHEISNAVREM 186 378 
MAP3K8 10; 30789749 SNV (C > T) DLGALAGYFNLVRGLPTLEYG 216 961 











Amino Acid Sequence 2 
Predicted Affinity 3 
mutated wild type 
DHDDS 1; 26646672 SNV (G > A) FLNVCFAYTSHHEISNAVREM 414 889 
FAM107B 10; 14603968 SNV (C > T) ELQKVMEKRKQDQVIKQKEEE 429 949 
1 Mutation location is from Ensembl build 54. The first number is the chromosome; the second 
indicates the first mutated nucleotide; 2 The indicated peptide sequences (21-mers) were screened 
for candidate epitopes of 8–11 amino acids in length. The minimal epitope with the highest 
predicted affinity is underlined. Amino acids that differ from the wildtype sequence are indicated in 
red; 3 Predicted affinity (nM) based on the NetMHC 3.2 prediction algorithm [59]. The NetMHC 
3.2 server predicts binding of peptides to a number of different HLA alleles using artificial neural 
networks (ANNs) and weight matrices [60-62]. Affinity scores of <50 nM indicate strong binding, 
whereas scores between 50 and 500 nM indicate weak binding. Similar data were obtained using a 
second prediction algorithm [63]; 4 Commonly used immunodominant peptides derived from 
cytomegalovirus (CMV pp65) [64] and melanoma (gp100280) [65] are highlighted in yellow;  
5 Please note that one limitation of next-generation sequencing technologies is that it can be very 
difficult to identify and validate small structural variants such as insertions or deletions. Robust 
computer algorithms have been established for the identification of these structural variants or 
indels [66]. Because indels are frequently frame shift mutations, they significantly alter the amino 
acid sequence, and may be more likely to be recognized by the immune system; 6 ● indicates  
stop codon. 
5. Implications for Cancer Vaccines 
Although cancer vaccines have been disappointing in the past [67], preliminary data from three 
large randomized phase III clinical trials have now demonstrated a statistically significant clinical 
benefit in lymphoma [68], prostate cancer [69], and melanoma [70], suggesting that cancer vaccines 
will have a clinical impact in these diseases in the near future. The results of tumor genome sequencing 
studies prompt the following questions related to the design of cancer vaccines: (1) What is the best 
strategy to target unique tumor antigens, a personalized vaccine approach, or an off-the-shelf vaccine 
approach targeting recurrent mutations? (2) Is it best to target candidate epitopes, or to design an 
unbiased strategy? (3) What is the best vaccine platform for targeting unique tumor antigens? 
5.1. Personalized or Off-The-Shelf Vaccine? 
The remarkable number of candidate unique tumor antigens that are predicted to bind patients’ HLA 
class I alleles underscores the potential of an unbiased personalized vaccine approach. Given the 
diversity of mutations observed, the limited number of recurrent mutations present in patients’ tumors, 
and the fact that off-the-shelf vaccines would be restricted by HLA type, we believe that relatively few 
cancer patients would be eligible for an off-the-shelf vaccine targeting the most common mutation(s). 
Even if multiple off-the-shelf vaccines were available, only a limited number of patients would be 
eligible. However, given the remarkable number of mutations consistently observed in cancer, it is 
likely that at least a subset of these mutations could be successfully targeted by a personalized  
vaccine approach. 
  




5.2. Candidate Epitope or Unbiased Approach? 
There are two conceptual strategies for creating a personalized cancer vaccine targeting unique 
tumor antigens: a candidate epitope approach, and an unbiased approach. The candidate epitope 
approach would use computer algorithms [52,56] to predict immunodominant epitopes, which could 
then be integrated into a personalized vaccine. Specifically targeting candidate epitopes has several 
advantages including ease of vaccine design and manufacture, streamlined immune monitoring, and 
prevention of immunodominance, a poorly understood process whereby cellular immunity is focused 
on one, or only a limited number of antigenic determinants, even during immune responses to complex 
antigens [71]. However, there are also disadvantages to a candidate epitope approach. Epitope 
prediction algorithms have significant limitations, particularly for less common HLA alleles, and 
validation of results would be costly and labor-intensive. Ultimately, it is not clear that computer 
algorithms or in vitro validation studies would be able to meaningfully predict the immunodominant 
antigens reliably. On balance, therefore, we believe that the unbiased approach is superior. In the 
unbiased approach, no attempt is made to identify the immunodominant epitopes, and all unique tumor 
antigens are integrated into a personalized vaccine. This approach is particularly attractive, as it has been 
predicted that not all unique tumor antigens are processed and presented by the immune system [54,72]. 
An unbiased approach, therefore, allows the immune system the opportunity to process and present the 
entire constellation of unique tumor antigens, maximizing the potential to successfully target the 
immunodominant epitope(s). An unbiased approach is also very feasible as DNA vaccines targeting 
multiple epitopes (polyepitope DNA vaccines) have been extensively evaluated in the infectious 
disease and cancer vaccine fields [73-76], taking advantage of the inherent flexibility of the DNA 
vaccine platform. 
5.3. Design of a Polyepitope DNA Vaccine 
The observation that direct administration of recombinant DNA can generate potent immune 
responses established the field of DNA vaccines in the early 1990s [77-82]. Since that time, DNA 
vaccines have remained an area of intense research interest, and vaccines targeting infectious disease 
and cancer have progressed into clinical trials. Advantages of the DNA vaccine platform include the 
remarkable safety profile of DNA vaccines, and the relative ease of manufacture relative to proteins 
and other biologics. Perhaps most important, however, is the molecular flexibility of the DNA vaccine 
platform, with the ability to genetically manipulate encoded antigens, and/or incorporate other genes to 
modulate immune response [83,84]. For instance DNA vaccines have been engineered to improve 
antigen expression [85-93], target dendritic cells [94,95], and/or coexpress molecular adjuvants 
capable of enhancing immune responses such as costimulatory molecules [96], cytokines [97-100], or 
chemokines [101]. For these reasons, we believe that the DNA vaccine platform is ideally suited to the 
clinical translation of a personalized cancer vaccine strategy. 
We propose an unbiased approach, integrating all of the candidate unique tumor antigens into a 
polyepitope DNA vaccine (Figure 3). Alternatively, analyzing tumor cells for expression of mutated 
antigens, e.g., by mRNA analysis could be implemented to select only for those mutations that are 
likely to be translated. This could be useful in case the number of mutations is considerably larger than 




the ~60 to 42 expected mutations in breast and colon cancer, respectively. Several in vitro and in vivo 
studies in mice and humans have validated such a polyepitope approach, demonstrating that 
vaccination with peptide, viral or DNA polyepitope constructs can successfully elicit CD8+ T cell 
responses [75,102-106]. Polyepitope vaccines using plasmid DNA or viral vectors have included 
greater than 30 contiguous immunodominant epitopes. Quite remarkably, most epitopes appear to be 
successfully processed and presented from the polyepitope constructs as determined by activation of 
antigen-specific CD8+ T cells. While these earlier polyepitope vaccines employed minimal peptide 
epitopes, i.e., 9–10 amino acid in length, an argument can be made for extension of each epitope to 
potentially include epitopes for several different HLA alleles, and potentially also include CD4 helper 
epitopes. Further optimizations, which may include (1) epitope length, (2) flanking sequences and 
proteolytic cleavage, and (3) fusion to ubiquitin and degradation, have the potential to greatly increase 
the immunogenicity of polyepitope DNA vaccines. 
Figure 3. Template of a polyepitope DNA vaccine. 
 
One potential drawback of cancer vaccine is the instability of HLA expression in the tumors. 
However, the conventional notion that cancers downregulate and/or lose classical HLA class I 
expression may not be accurate in all cancers [107]. Experimental results and clinical data have 
demonstrated that the expression of HLA antigens can be retained in some tumors. Furthermore, some 
dysplastic and malignant cells can even acquire or upregulate HLA class I expression. Cancer cells are 
under continuous selective pressure from host’s immune system (immunoediting) [26]. Therefore, the 
status of HLA expression on cancer cells is the results of a complex interplay between the tumor cells, 
the immune system, and the tumor microenvironment [107]. Nevertheless, the changes in HLA 
expression in cancer can profoundly affect the efficacy of any cancer immunotherapy. 
5.4. Clinical Translation of Genome Sequencing Data into Personalized Cancer Vaccines 
The development of cancer vaccines is an area of intense investigation and considerable yet 
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immunotherapy. We anticipate and excitedly await the development of a new generation of vaccines 
specifically targeting unique antigens expressed exclusively by a patient’s tumor. 
Conflict of Interest 
The authors declare no conflict of interest. 
Acknowledgements 
Sources of support: Susan G. Komen for the Cure PDF Award KG080476 (W.E.G. and L.L.);  
Susan G. Komen for the Cure Promise Award KG111025 (W.E.G. and T.H.H.); and Frank Cancer 
Research Fund, awarded by the Barnes-Jewish Hospital Foundation (P.G.). 
References 
1. Lander, E.S.; Linton, L.M.; Birren, B.; Nusbaum, C.; Zody, M.C.; Baldwin, J.; Devon, K.; 
Dewar, K.; Doyle, M.; FitzHugh, W.; et al. Initial sequencing and analysis of the human genome. 
Nature 2001, 409, 860-921. 
2. Venter, J.C.; Adams, M.D.; Myers, E.W.; Li, P.W.; Mural, R.J.; Sutton, G.G.; Smith, H.O.; 
Yandell, M.; Evans, C.A.; Holt, R.A.; et al. The sequence of the human genome. Science 2001, 
291, 1304-1351. 
3. Mardis, E.R. A decade’s perspective on DNA sequencing technology. Nature 2011, 470, 198-203. 
4. Pettersson, E.; Lundeberg, J.; Ahmadian, A. Generations of sequencing technologies. Genomics 
2009, 93, 105-111. 
5. Mardis, E.R. Next-generation DNA sequencing methods. Annu. Rev. Genomics Hum. Genet. 
2008, 9, 387-402. 
6. Anderson, M.W.; Schrijver, I. Next generation DNA sequencing and the future of genomic 
medicine. Genes 2010, 1, 38-69. 
7. Porreca, G.J. Genome sequencing on nanoballs. Nat. Biotechnol. 2010, 28, 43-44. 
8. Drmanac, R.; Sparks, A.B.; Callow, M.J.; Halpern, A.L.; Burns, N.L.; Kermani, B.G.; Carnevali, P.; 
Nazarenko, I.; Nilsen, G.B.; Yeung, G.; et al. Human genome sequencing using unchained base 
reads on self-assembling DNA nanoarrays. Science 2010, 327, 78-81. 
9. Rothberg, J.M.; Hinz, W.; Rearick, T.M.; Schultz, J.; Mileski, W.; Davey, M.; Leamon, J.H.; 
Johnson, K.; Milgrew, M.J.; Edwards, M.; et al. An integrated semiconductor device enabling 
non-optical genome sequencing. Nature 2011, 475, 348-352. 
10. Thompson, J.F.; Milos, P.M. The properties and applications of single-molecule DNA 
sequencing. Genome Biol. 2011, 12, 217. 
11. Eid, J.; Fehr, A.; Gray, J.; Luong, K.; Lyle, J.; Otto, G.; Peluso, P.; Rank, D.; Baybayan, P.; 
Bettman, B.; et al. Real-time DNA sequencing from single polymerase molecules. Science 2009, 
323, 133-138. 
12. Wetterstrand, K.A. DNA sequencing costs: Data from the NHGRI large-scale genome 
sequencing program. Available online: http://www.genome.gov/sequencingcosts/ (accessed on 
24 October 2011). 




13. Ding, L.; Ellis, M.J.; Li, S.; Larson, D.E.; Chen, K.; Wallis, J.W.; Harris, C.C.; McLellan, M.D.; 
Fulton, R.S.; Fulton, L.L.; et al. Genome remodelling in a basal-like breast cancer metastasis and 
xenograft. Nature 2010, 464, 999-1005. 
14. Ley, T.J.; Mardis, E.R.; Ding, L.; Fulton, B.; McLellan, M.D.; Chen, K.; Dooling, D.;  
Dunford-Shore, B.H.; McGrath, S.; Hickenbotham, M.; et al. DNA sequencing of a cytogenetically 
normal acute myeloid leukaemia genome. Nature 2008, 456, 66-72. 
15. Pleasance, E.D.; Stephens, P.J.; O'Meara, S.; McBride, D.J.; Meynert, A.; Jones, D.; Lin, M.L.; 
Beare, D.; Lau, K.W.; Greenman, C.; et al. A small-cell lung cancer genome with complex 
signatures of tobacco exposure. Nature 2010, 463, 184-190. 
16. Wood, L.D.; Parsons, D.W.; Jones, S.; Lin, J.; Sjoblom, T.; Leary, R.J.; Shen, D.; Boca, S.M.; 
Barber, T.; Ptak, J.; et al. The genomic landscapes of human breast and colorectal cancers. 
Science 2007, 318, 1108-1113. 
17. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646-674. 
18. Der, C.J.; Krontiris, T.G.; Cooper, G.M. Transforming genes of human bladder and lung 
carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. 
Proc. Natl. Acad. Sci. USA 1982, 79, 3637-3640. 
19. Parada, L.F.; Tabin, C.J.; Shih, C.; Weinberg, R.A. Human EJ bladder carcinoma oncogene is 
homologue of Harvey sarcoma virus ras gene. Nature 1982, 297, 474-478. 
20. Santos, E.; Tronick, S.R.; Aaronson, S.A.; Pulciani, S.; Barbacid, M. T24 human bladder 
carcinoma oncogene is an activated form of the normal human homologue of BALB- and 
Harvey-MSV transforming genes. Nature 1982, 298, 343-347. 
21. Miki, Y.; Swensen, J.; Shattuck-Eidens, D.; Futreal, P.A.; Harshman, K.; Tavtigian, S.; Liu, Q.; 
Cochran, C.; Bennett, L.M.; Ding, W.; et al. A strong candidate for the breast and ovarian cancer 
susceptibility gene BRCA1. Science 1994, 266, 66-71. 
22. Wooster, R.; Bignell, G.; Lancaster, J.; Swift, S.; Seal, S.; Mangion, J.; Collins, N.; Gregory, S.; 
Gumbs, C.; Micklem, G. Identification of the breast cancer susceptibility gene BRCA2. Nature 
1995, 378, 789-792. 
23. Golub, T.R.; Slonim, D.K.; Tamayo, P.; Huard, C.; Gaasenbeek, M.; Mesirov, J.P.; Coller, H.; 
Loh, M.L.; Downing, J.R.; Caligiuri, M.A.; et al. Molecular classification of cancer: Class 
discovery and class prediction by gene expression monitoring. Science 1999, 286, 531-537. 
24. Welch, J.S.; Westervelt, P.; Ding, L.; Larson, D.E.; Klco, J.M.; Kulkarni, S.; Wallis, J.; Chen, K.; 
Payton, J.E.; Fulton, R.S.; et al. Use of whole-genome sequencing to diagnose a cryptic fusion 
oncogene. JAMA 2011, 305, 1577-1584. 
25. Link, D.C.; Schuettpelz, L.G.; Shen, D.; Wang, J.; Walter, M.J.; Kulkarni, S.; Payton, J.E.; 
Ivanovich, J.; Goodfellow, P.J.; Le Beau, M.; et al. Identification of a novel TP53 cancer 
susceptibility mutation through whole-genome sequencing of a patient with therapy-related 
AML. JAMA 2011, 305, 1568-1576. 
26. Dunn, G.P.; Old, L.J.; Schreiber, R.D. The three Es of cancer immunoediting. Annu. Rev. 
Immunol. 2004, 22, 329-360. 
27. Lesterhuis, W.J.; Haanen, J.B.; Punt, C.J. Cancer immunotherapy—Revisited. Nat. Rev. Drug 
Discov. 2011, 10, 591-600. 




28. Postow, M.; Callahan, M.K.; Wolchok, J.D. Beyond cancer vaccines: A reason for future 
optimism with immunomodulatory therapy. Cancer J. 2011, 17, 372-378. 
29. van der Bruggen, P.; Traversari, C.; Chomez, P.; Lurquin, C.; de Plaen, E.; van den Eynde, B.; 
Knuth, A.; Boon, T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a 
human melanoma. Science 1991, 254, 1643-1647. 
30. Peshwa, M.V.; Shi, J.D.; Ruegg, C.; Laus, R.; van Schooten, W.C. Induction of prostate  
tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with 
prostatic acid phosphatase peptide. Prostate 1998, 36, 129-138. 
31. Peoples, G.E.; Goedegebuure, P.S.; Smith, R.; Linehan, D.C.; Yoshino, I.; Eberlein, T.J. Breast 
and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived 
peptide. Proc. Natl. Acad. Sci. USA 1995, 92, 432-436. 
32. Parmiani, G.; de Filippo, A.; Novellino, L.; Castelli, C. Unique human tumor antigens: 
Immunobiology and use in clinical trials. J. Immunol. 2007, 178, 1975-1979. 
33. Sensi, M.; Anichini, A. Unique tumor antigens: Evidence for immune control of genome 
integrity and immunogenic targets for T cell-mediated patient-specific immunotherapy.  
Clin. Cancer Res. 2006, 12, 5023-5032. 
34. Coulie, P.G.; Lehmann, F.; Lethe, B.; Herman, J.; Lurquin, C.; Andrawiss, M.; Boon, T.  
A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes 
on a human melanoma. Proc. Natl. Acad. Sci. USA 1995, 92, 7976-7980. 
35. Wolfel, T.; Hauer, M.; Schneider, J.; Serrano, M.; Wolfel, C.; Klehmann-Hieb, E.; de Plaen, E.; 
Hankeln, T.; Meyer zum Buschenfelde, K.H.; Beach, D. A p16INK4a-insensitive CDK4 mutant 
targeted by cytolytic T lymphocytes in a human melanoma. Science 1995, 269, 1281-1284. 
36. Wang, R.F.; Wang, X.; Atwood, A.C.; Topalian, S.L.; Rosenberg, S.A. Cloning genes encoding 
MHC class II-restricted antigens: Mutated CDC27 as a tumor antigen. Science 1999, 284, 1351-1354. 
37. Echchakir, H.; Mami-Chouaib, F.; Vergnon, I.; Baurain, J.F.; Karanikas, V.; Chouaib, S.;  
Coulie, P.G. A point mutation in the alpha-actinin-4 gene generates an antigenic peptide 
recognized by autologous cytolytic T lymphocytes on a human lung carcinoma. Cancer Res. 
2001, 61, 4078-4083. 
38. Brandle, D.; Brasseur, F.; Weynants, P.; Boon, T.; van den Eynde, B. A mutated HLA-A2 
molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma.  
J. Exp. Med. 1996, 183, 2501-2508. 
39. Disis, M.L.; Calenoff, E.; McLaughlin, G.; Murphy, A.E.; Chen, W.; Groner, B.; Jeschke, M.; 
Lydon, N.; McGlynn, E.; Livingston, R.B.; et al. Existent T-cell and antibody immunity to  
HER-2/neu protein in patients with breast cancer. Cancer Res. 1994, 54, 16-20. 
40. Disis, M.L.; Knutson, K.L.; Schiffman, K.; Rinn, K.; McNeel, D.G. Pre-existent immunity to the 
HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian 
cancer. Breast Cancer Res. Treat. 2000, 62, 245-252. 
41. von Mensdorff-Pouilly, S.; Snijdewint, F.G.; Verstraeten, A.A.; Verheijen, R.H.; Kenemans, P. 
Human MUC1 mucin: A multifaceted glycoprotein. Int. J. Biol. Markers 2000, 15, 343-356. 
42. Jaramillo, A.; Majumder, K.; Manna, P.P.; Fleming, T.P.; Doherty, G.; Dipersio, J.F.; 
Mohanakumar, T. Identification of HLA-A3-restricted CD8+ T cell epitopes derived from 
mammaglobin-A, a tumor-associated antigen of human breast cancer. Int. J. Cancer 2002, 102, 
499-506. 




43. Jaramillo, A.; Narayanan, K.; Campbell, L.G.; Benshoff, N.D.; Lybarger, L.; Hansen, T.H.; 
Fleming, T.P.; Dietz, J.R.; Mohanakumar, T. Recognition of HLA-A2-restricted  
mammaglobin-A-derived epitopes by CD8+ cytotoxic T lymphocytes from breast cancer patients. 
Breast Cancer Res. Treat. 2004, 88, 29-41. 
44. Narayanan, K.; Jaramillo, A.; Benshoff, N.D.; Campbell, L.G.; Fleming, T.P.; Dietz, J.R.; 
Mohanakumar, T. Response of established human breast tumors to vaccination with 
mammaglobin-A cDNA. J. Natl. Cancer Inst. 2004, 96, 1388-1396. 
45. Parmiani, G.; Sensi, M.; Castelli, C.; Rivoltini, L.; Anichini, A. T-cell response to unique and 
shared antigens and vaccination of cancer patients. Cancer Immun. 2002, 2, 6. 
46. Rosenberg, S.A.; Yang, J.C.; Restifo, N.P. Cancer immunotherapy: Moving beyond current 
vaccines. Nat. Med. 2004, 10, 909-915. 
47. Rosenberg, S.A.; Sherry, R.M.; Morton, K.E.; Scharfman, W.J.; Yang, J.C.; Topalian, S.L.; 
Royal, R.E.; Kammula, U.; Restifo, N.P.; Hughes, M.S.; et al. Tumor progression can occur 
despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients 
with melanoma. J. Immunol. 2005, 175, 6169-6176. 
48. Nishikawa, H.; Jager, E.; Ritter, G.; Old, L.J.; Gnjatic, S. CD4+ CD25+ regulatory T cells control 
the induction of antigen-specific CD4+ helper T cell responses in cancer patients. Blood 2005, 
106, 1008-1011. 
49. Rahma, O.E.; Ashtar, E.; Ibrahim, R.; Toubaji, A.; Gause, B.; Herrin, V.E.; Linehan, W.M.; 
Steinberg, S.M.; Grollman, F.; Grimes, G.; et al. A pilot clinical trial testing mutant von  
Hippel-Lindau peptide as a novel immune therapy in metastatic renal cell carcinoma. J. Transl. 
Med. 2010, 8, 8. 
50. Bendandi, M.; Gocke, C.D.; Kobrin, C.B.; Benko, F.A.; Sternas, L.A.; Pennington, R.;  
Watson, T.M.; Reynolds, C.W.; Gause, B.L.; Duffey, P.L.; et al. Complete molecular remissions 
induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor 
against lymphoma. Nat. Med. 1999, 5, 1171-1177. 
51. Schuster, S.J.; Neelapu, S.S.; Gause, B.L.; Janik, J.E.; Muggia, F.M.; Gockerman, J.P.; Winter, J.N.; 
Flowers, C.R.; Nikcevich, D.A.; Sotomayor, E.M.; et al. Vaccination with patient-specific 
tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma.  
J. Clin. Oncol. 2011, 29, 2787-2794. 
52. Rammensee, H.; Bachmann, J.; Emmerich, N.P.; Bachor, O.A.; Stevanovic, S. SYFPEITHI: 
Database for MHC ligands and peptide motifs. Immunogenetics 1999, 50, 213-219. 
53. Gilboa, E. The makings of a tumor rejection antigen. Immunity 1999, 11, 263-270. 
54. Segal, N.H.; Parsons, D.W.; Peggs, K.S.; Velculescu, V.; Kinzler, K.W.; Vogelstein, B.; Allison, J.P. 
Epitope landscape in breast and colorectal cancer. Cancer Res. 2008, 68, 889-892. 
55. Sjoblom, T.; Jones, S.; Wood, L.D.; Parsons, D.W.; Lin, J.; Barber, T.D.; Mandelker, D.; Leary, R.J.; 
Ptak, J.; Silliman, N.; et al. The consensus coding sequences of human breast and colorectal 
cancers. Science 2006, 314, 268-274. 
56. Parker, K.C.; Bednarek, M.A.; Coligan, J.E. Scheme for ranking potential HLA-A2 binding 
peptides based on independent binding of individual peptide side-chains. J. Immunol. 1994, 152, 
163-175. 




57. Ley, T.J.; Ding, L.; Walter, M.J.; McLellan, M.D.; Lamprecht, T.; Larson, D.E.; Kandoth, C.; 
Payton, J.E.; Baty, J.; Welch, J.; et al. DNMT3A mutations in acute myeloid leukemia. N. Engl. 
J. Med. 2010, 363, 2424-2433. 
58. Mardis, E.R.; Ding, L.; Dooling, D.J.; Larson, D.E.; McLellan, M.D.; Chen, K.; Koboldt, D.C.; 
Fulton, R.S.; Delehaunty, K.D.; McGrath, S.D.; et al. Recurring mutations found by sequencing 
an acute myeloid leukemia genome. N. Engl. J. Med. 2009, 361, 1058-1066. 
59. NetMHC 3.2 server. Available online: http://www.cbs.dtu.dk/services/NetMHC/ (accessed on  
24 October 2011). 
60. Buus, S.; Lauemoller, S.L.; Worning, P.; Kesmir, C.; Frimurer, T.; Corbet, S.; Fomsgaard, A.; 
Hilden, J.; Holm, A.; Brunak, S. Sensitive quantitative predictions of peptide-MHC binding by a 
‘query by committee’ artificial neural network approach. Tissue Antigens 2003, 62, 378-384. 
61. Lundegaard, C.; Lamberth, K.; Harndahl, M.; Buus, S.; Lund, O.; Nielsen, M. NetMHC-3.0: 
Accurate web accessible predictions of human, mouse and monkey MHC class I affinities for 
peptides of length 8–11. Nucleic Acids Res. 2008, 36, W509-W512. 
62. Nielsen, M.; Lundegaard, C.; Worning, P.; Lauemoller, S.L.; Lamberth, K.; Buus, S.; Brunak, S.; 
Lund, O. Reliable prediction of T-cell epitopes using neural networks with novel sequence 
representations. Protein Sci. 2003, 12, 1007-1017. 
63. A database of MHC ligands and peptide motifs (Ver.1.0). Available online: http://www.syfpeithi.de/ 
(accessed on 24 October 2011). 
64. Wills, M.R.; Carmichael, A.J.; Mynard, K.; Jin, X.; Weekes, M.P.; Plachter, B.; Sissons, J.G. 
The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by 
structural protein pp65: Frequency, specificity, and T-cell receptor usage of pp65-specific CTL.  
J. Virol. 1996, 70, 7569-7579. 
65. Tsai, V.; Southwood, S.; Sidney, J.; Sakaguchi, K.; Kawakami, Y.; Appella, E.; Sette, A.; Celis, E. 
Identification of subdominant CTL epitopes of the gp100 melanoma-associated tumor antigen by 
primary in vitro immunization with peptide-pulsed dendritic cells. J. Immunol. 1997, 158,  
1796-1802. 
66. Chen, K.; Wallis, J.W.; McLellan, M.D.; Larson, D.E.; Kalicki, J.M.; Pohl, C.S.; McGrath, S.D.; 
Wendl, M.C.; Zhang, Q.; Locke, D.P.; et al. Breakdancer: An algorithm for high-resolution 
mapping of genomic structural variation. Nat. Methods 2009, 6, 677-681. 
67. Goldman, B.; DeFrancesco, L. The cancer vaccine roller coaster. Nat. Biotechnol. 2009, 27, 129-139. 
68. Schuster, S.J.; Neelapu, S.S.; Gause, B.L.; Muggia, F.M.; Gockerman, J.P.; Sotomayor, E.M.; 
Winter, J.N.; Flowers, C.R.; Stergiou, A.M.; Kwak, L.W. Idiotype vaccine therapy (biovaxid) in 
follicular lymphoma in first complete remission: Phase III clinical trial results. J. Clin. Oncol. 
2009, 27, 2. 
69. Schellhammer, P.F.; Berger, E.R.; Shore, N.; Small, E.J.; Penson, D.; Ferrari, A.; Sims, R.; Yuh, L.; 
Frohlich, M.; Kantoff, P. A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III 
Trial of Sipuleucel-T in Men with Metastatic, Androgen Independent Prostatic Adenocarcinoma 
(AIPC). In American Urological Association 104th Annual Meeting, Chicago, IL, USA,  
25–30 April 2009. 
  




70. Schwartzentruber, D.J.; Lawson, D.; Richards, J.; Conry, R.M.; Miller, D.; Triesman, J.; Gailani, F.; 
Riley, L.B.; Vena, D.; Hwu, P. A phase III multi-institutional randomized study of immunization 
with the gp100: 209-217(210M) peptide followed by high-dose IL-2 compared with high-dose 
IL-2 alone in patients with metastatic melanoma. J. Clin. Oncol. 2009, 27, CRA9011. 
71. Chen, W.; McCluskey, J. Immunodominance and immunodomination: Critical factors in 
developing effective CD8+ T-cell-based cancer vaccines. Adv. Cancer Res. 2006, 95, 203-247. 
72. Srivastava, N.; Srivastava, P.K. Modeling the repertoire of true tumor-specific MHC I epitopes in 
a human tumor. PLoS ONE 2009, 4, e6094. 
73. Bazhan, S.I.; Karpenko, L.I.; Ilyicheva, T.N.; Belavin, P.A.; Seregin, S.V.; Danilyuk, N.K.; 
Antonets, D.V.; Ilyichev, A.A. Rational design based synthetic polyepitope DNA vaccine for 
eliciting HIV-specific CD8+ T cell responses. Mol. Immunol. 2010, 47, 1507-1515. 
74. Cardinaud, S.; Bouziat, R.; Rohrlich, P.S.; Tourdot, S.; Weiss, L.; Langlade-Demoyen, P.; 
Burgevin, A.; Fiorentino, S.; van Endert, P.; Lemonnier, F.A. Design of a HIV-1-derived  
HLA-B07.02-restricted polyepitope construct. AIDS 2009, 23, 1945-1954. 
75. Scardino, A.; Alimandi, M.; Correale, P.; Smith, S.G.; Bei, R.; Firat, H.; Cusi, M.G.; Faure, O.; 
Graf-Dubois, S.; Cencioni, G.; et al. A polyepitope DNA vaccine targeted to Her-2/ErbB-2 
elicits a broad range of human and murine CTL effectors to protect against tumor challenge. 
Cancer Res. 2007, 67, 7028-7036. 
76. Velders, M.P.; Weijzen, S.; Eiben, G.L.; Elmishad, A.G.; Kloetzel, P.M.; Higgins, T.;  
Ciccarelli, R.B.; Evans, M.; Man, S.; Smith, L.; et al. Defined flanking spacers and enhanced 
proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine.  
J. Immunol. 2001, 166, 5366-5373. 
77. Cox, G.J.; Zamb, T.J.; Babiuk, L.A. Bovine herpesvirus 1: Immune responses in mice and cattle 
injected with plasmid DNA. J. Virol. 1993, 67, 5664-5667. 
78. Davis, H.L.; Michel, M.L.; Whalen, R.G. DNA-based immunization induces continuous 
secretion of hepatitis B surface antigen and high levels of circulating antibody. Hum. Mol. Genet. 
1993, 2, 1847-1851. 
79. Fynan, E.F.; Webster, R.G.; Fuller, D.H.; Haynes, J.R.; Santoro, J.C.; Robinson, H.L. DNA 
vaccines: Protective immunizations by parenteral, mucosal, and gene-gun inoculations.  
Proc. Natl. Acad. Sci. USA 1993, 90, 11478-11482. 
80. Tang, D.C.; DeVit, M.; Johnston, S.A. Genetic immunization is a simple method for eliciting an 
immune response. Nature 1992, 356, 152-154. 
81. Ulmer, J.B.; Donnelly, J.J.; Parker, S.E.; Rhodes, G.H.; Felgner, P.L.; Dwarki, V.J.; 
Gromkowski, S.H.; Deck, R.R.; DeWitt, C.M.; Friedman, A.; et al. Heterologous protection 
against influenza by injection of DNA encoding a viral protein. Science 1993, 259, 1745-1749. 
82. Wang, B.; Ugen, K.E.; Srikantan, V.; Agadjanyan, M.G.; Dang, K.; Refaeli, Y.; Sato, A.I.; 
Boyer, J.; Williams, W.V.; Weiner, D.B. Gene inoculation generates immune responses against 
human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 1993, 90, 4156-4160. 
83. Donnelly, J.J.; Ulmer, J.B.; Shiver, J.W.; Liu, M.A. DNA vaccines. Annu. Rev. Immunol. 1997, 
15, 617-648. 
84. Gurunathan, S.; Klinman, D.M.; Seder, R.A. DNA vaccines: Immunology, application, and 
optimization*. Annu. Rev. Immunol. 2000, 18, 927-974. 




85. Andre, S.; Seed, B.; Eberle, J.; Schraut, W.; Bultmann, A.; Haas, J. Increased immune response 
elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage.  
J. Virol. 1998, 72, 1497-1503. 
86. Huang, C.H.; Peng, S.; He, L.; Tsai, Y.C.; Boyd, D.A.; Hansen, T.H.; Wu, T.C.; Hung, C.F. 
Cancer immunotherapy using a DNA vaccine encoding a single-chain trimer of MHC class I 
linked to an HLA-16 E6 immunodominant ctl epitope. Gene Ther. 2005, 12, 1180-1186. 
87. Kim, S.; Li, L.; McMurtrey, C.P.; Hildebrand, W.H.; Weidanz, J.A.; Gillanders, W.E.;  
Diamond, M.S.; Hansen, T.H. Single-chain HLA-A2 MHC trimers that incorporate an 
immundominant peptide elicit protective T cell immunity against lethal west nile virus infection. 
J. Immunol. 2010, 184, 4423-4430. 
88. Lee, A.H.; Suh, Y.S.; Sung, J.H.; Yang, S.H.; Sung, Y.C. Comparison of various expression 
plasmids for the induction of immune response by DNA immunization. Mol. Cells 1997, 7, 495-501. 
89. Li, L.; Herndon, J.M.; Truscott, S.M.; Hansen, T.H.; Fleming, T.P.; Goedegebuure, P.; 
Gillanders, W.E. Engineering superior DNA vaccines: MHC class I single chain trimers bypass 
antigen processing and enhance the immune response to low affinity antigens. Vaccine 2010, 28, 
1911-1918. 
90. Lybarger, L.; Yu, Y.Y.; Miley, M.J.; Fremont, D.H.; Myers, N.; Primeau, T.; Truscott, S.M.; 
Connolly, J.M.; Hansen, T.H. Enhanced immune presentation of a single-chain major 
histocompatibility complex class I molecule engineered to optimize linkage of a C-terminally 
extended peptide. J. Biol. Chem. 2003, 278, 27105-27111. 
91. Mitaksov, V.; Truscott, S.M.; Lybarger, L.; Connolly, J.M.; Hansen, T.H.; Fremont, D.H. 
Structural engineering of pMHC reagents for T cell vaccines and diagnostics. Chem. Biol. 2007, 
14, 909-922. 
92. Truscott, S.M.; Lybarger, L.; Martinko, J.M.; Mitaksov, V.E.; Kranz, D.M.; Connolly, J.M.; 
Fremont, D.H.; Hansen, T.H. Disulfide bond engineering to trap peptides in the MHC class I 
binding groove. J. Immunol. 2007, 178, 6280-6289. 
93. Yu, Y.Y.; Netuschil, N.; Lybarger, L.; Connolly, J.M.; Hansen, T.H. Cutting edge: Single-chain 
trimers of MHC class I molecules form stable structures that potently stimulate antigen-specific 
T cells and B cells. J. Immunol. 2002, 168, 3145-3149. 
94. Nchinda, G.; Kuroiwa, J.; Oks, M.; Trumpfheller, C.; Park, C.G.; Huang, Y.; Hannaman, D.; 
Schlesinger, S.J.; Mizenina, O.; Nussenzweig, M.C.; et al. The efficacy of DNA vaccination is 
enhanced in mice by targeting the encoded protein to dendritic cells. J. Clin. Invest. 2008, 118, 
1427-1436. 
95. Trumpfheller, C.; Finke, J.S.; Lopez, C.B.; Moran, T.M.; Moltedo, B.; Soares, H.; Huang, Y.; 
Schlesinger, S.J.; Park, C.G.; Nussenzweig, M.C.; et al. Intensified and protective CD4+ T cell 
immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine. J. Exp. Med. 2006, 
203, 607-617. 
96. Chan, K.; Lee, D.J.; Schubert, A.; Tang, C.M.; Crain, B.; Schoenberger, S.P.; Corr, M. The roles 
of MHC class II, CD40, and B7 costimulation in CTL induction by plasmid DNA. J. Immunol. 
2001, 166, 3061-3066. 
  




97. Boyer, J.D.; Robinson, T.M.; Kutzler, M.A.; Parkinson, R.; Calarota, S.A.; Sidhu, M.K.; 
Muthumani, K.; Lewis, M.; Pavlakis, G.; Felber, B.; et al. SIV DNA vaccine co-administered 
with IL-12 expression plasmid enhances CD8 SIV cellular immune responses in cynomolgus 
macaques. J. Med. Primatol. 2005, 34, 262-270. 
98. Chong, S.Y.; Egan, M.A.; Kutzler, M.A.; Megati, S.; Masood, A.; Roopchard, V.; Garcia-Hand, D.; 
Montefiori, D.C.; Quiroz, J.; Rosati, M.; et al. Comparative ability of plasmid IL-12 and IL-15 to 
enhance cellular and humoral immune responses elicited by a SIVgag plasmid DNA vaccine and 
alter disease progression following SHIV(89.6P) challenge in rhesus macaques. Vaccine 2007, 
25, 4967-4982. 
99. Hirao, L.A.; Wu, L.; Khan, A.S.; Hokey, D.A.; Yan, J.; Dai, A.; Betts, M.R.; Draghia-Akli, R.; 
Weiner, D.B. Combined effects of IL-12 and electroporation enhances the potency of DNA 
vaccination in macaques. Vaccine 2008, 26, 3112-3120. 
100. Schadeck, E.B.; Sidhu, M.; Egan, M.A.; Chong, S.Y.; Piacente, P.; Masood, A.; Garcia-Hand, D.; 
Cappello, S.; Roopchand, V.; Megati, S.; et al. A dose sparing effect by plasmid encoded IL-12 
adjuvant on a SIVgag-plasmid DNA vaccine in rhesus macaques. Vaccine 2006, 24, 4677-4687. 
101. Sumida, S.M.; McKay, P.F.; Truitt, D.M.; Kishko, M.G.; Arthur, J.C.; Seaman, M.S.; Jackson, S.S.; 
Gorgone, D.A.; Lifton, M.A.; Letvin, N.L.; et al. Recruitment and expansion of dendritic cells in vivo 
potentiate the immunogenicity of plasmid DNA vaccines. J. Clin. Invest. 2004, 114, 1334-1342. 
102. Nielsen, J.S.; Wick, D.A.; Tran, E.; Nelson, B.H.; Webb, J.R. An in vitro-transcribed-mRNA 
polyepitope construct encoding 32 distinct HLA class I-restricted epitopes from CMV, EBV, and 
influenza for use as a functional control in human immune monitoring studies. J. Immunol. 
Methods 2010, 360, 149-156. 
103. Iglesias, M.C.; Mollier, K.; Beignon, A.S.; Souque, P.; Adotevi, O.; Lemonnier, F.; Charneau, P. 
Lentiviral vectors encoding HIV-1 polyepitopes induce broad CTL responses in vivo. Mol. Ther. 
2007, 15, 1203-1210. 
104. Ding, F.X.; Wang, F.; Lu, Y.M.; Li, K.; Wang, K.H.; He, X.W.; Sun, S.H. Multiepitope  
peptide-loaded virus-like particles as a vaccine against hepatitis B virus-related hepatocellular 
carcinoma. Hepatology 2009, 49, 1492-1502. 
105. Depla, E.; van der Aa, A.; Livingston, B.D.; Crimi, C.; Allosery, K.; de Brabandere, V.; 
Krakover, J.; Murthy, S.; Huang, M.; Power, S.; et al. Rational design of a multiepitope vaccine 
encoding T-lymphocyte epitopes for treatment of chronic hepatitis B virus infections. J. Virol. 
2008, 82, 435-450. 
106. Alexander, J.; Oseroff, C.; Dahlberg, C.; Qin, M.; Ishioka, G.; Beebe, M.; Fikes, J.; Newman, M.; 
Chesnut, R.W.; Morton, P.A.; et al. A decaepitope polypeptide primes for multiple CD8+  
IFN-gamma and Th lymphocyte responses: Evaluation of multiepitope polypeptides as a mode 
for vaccine delivery. J. Immunol. 2002, 168, 6189-6198. 
107. Campoli, M.; Ferrone, S. HLA antigen and NK cell activating ligand expression in malignant 
cells: A story of loss or acquisition. Semin. Immunopathol. 2011, 33, 321-334. 
© 2011 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 
